# Orthofix Medical Q3 2026 Earnings Results

> Orthofix Medical reports Q3 2026 earnings below expectations with U.S. Spine weakness but strong limb reconstruction growth.
- Title: Orthofix Medical Q3 2026 Earnings Results · The Motley Fool
- Summary: Orthofix Medical reports Q3 2026 earnings below expectations with U.S. Spine weakness but strong limb reconstruction growth.
- Keywords: orthofix medical, q3 2026, earnings call, spine fixation, limb reconstruction, therapeutic solutions, fitbone, truelok elevate, mdr regulation, The Motley Fool
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/11/09/orthofix-medical-ofix-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-11-09T16:53:24+00:00
- Read time: 2 min
- Topics: orthofix medical, q3 2026, earnings call, spine fixation, limb reconstruction, therapeutic solutions, fitbone, truelok elevate, mdr regulation, finance, money
## Q3 2026 Results
Orthofix Medical reported Q3 2026 net sales of $207.9 million, a 2.3% increase on a pro forma constant currency basis.
## Net Loss
Net loss of $6.1 million, or $0.15 per share, compared to a net loss of $22.8 million in the prior year period.
## Adjusted EBITDA
Adjusted EBITDA of $26.0 million, representing 12.5% of pro forma net sales compared to 12.1% in the third quarter of 2025.
## Spine Segment
U.S. Spine Fixation revenue declined 5% year over year due to market-driven procedural softness and supplier delays.
## Limb Reconstruction
Global Limb Reconstruction net sales grew 9% on a constant currency basis driven by strong international demand.
## Therapeutic Solutions
Therapeutic Solutions net sales grew 4% year over year and exceeded general market growth rates.
## FITBONE and TrueLok
FITBONE and TrueLok Elevate grew over 20% in the third quarter, driving performance in the Global Limb Reconstruction segment.
## Full Year Guidance
Full year net sales guidance revised to $825 million to $830 million, down from $845 million to $855 million.
## European MDR Headwind
Expected $22 million net sales headwind in 2027 due to European Medical Device Regulation requirements.
## Cash Position
Cash and cash equivalents of $86.9 million as of September 30, 2026, reflecting working capital timing.
## Distributor Strategy
Core distributors now generate 80% of U.S. spinal implant revenue after accelerating exits from nonstrategic relationships.
## Product Portfolio
Company simplifying product portfolio to focus on high-growth technologies like VIRATA and 7D navigation.
## VIRATA Launch
Full market launch of VIRATA spinal implant system for open procedures expected later in the fourth quarter.
## 7D Navigation
Received two 510(k) clearances for software enhancements to the 7D navigation system.
## Biologics Performance
U.S. Biologics returned to positive year-over-year growth in October after remaining flat sequentially.
## European Distributor
$15 million net sales benefit expected in 2026 from European distributor arrangement, mostly in fourth quarter.
## Key takeaway

Orthofix Medical reported Q3 2026 net sales of $207.9 million, a 2.3% increase, but U.S. Spine Fixation declined 5% year over year due to market softness and supplier delays.